While our findings showed that the knockdown of ANXA10 induced ferroptosis and hindered the malignant proliferation and migration of CRC cells, it remains unclear whether the ferroptosis triggered by ANXA10 downregulation can enhance the sensitivity of existing chemotherapy, targeted therapy, or immunotherapy regimens. This evidence concerns the gene ANXA10 and colorectal carcinoma.